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REVIEW ESSAYSEpigenetic and Transcriptional Variability Shape
Phenotypic PlasticitySimone Ecker,* Vera Pancaldi, Alfonso Valencia, Stephan Beck, and Dirk S. PaulEpigenetic and transcriptional variability contribute to the vast diversity of
cellular and organismal phenotypes and are key in human health and disease.
In this review, we describe different types, sources, and determinants of
epigenetic and transcriptional variability, enabling cells and organisms to adapt
and evolve to a changing environment. We highlight the latest research and
hypotheses on how chromatin structure and the epigenome influence gene
expression variability. Further, we provide an overview of challenges in the
analysis of biological variability. An improved understanding of the molecular
mechanisms underlying epigenetic and transcriptional variability, at both
the intra- and inter-individual level, provides great opportunity for disease
prevention, better therapeutic approaches, and personalized medicine.1. Introduction
No two cells in a cellular population are the same, and no two
individuals of a multi-cellular species are identical—not even if
they share the same genetic makeup like monozygotic twins or
cloned animals. Even cells or model organisms with the same
genotype that are grown under the exact same laboratory
conditions can display variability in appearance and behavior.[1,2]Dr. S. Ecker, Prof. S. Beck
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organismhaveessentially thesamegenome,
but exhibit many different phenotypes. This
is due to epigenetic and transcriptional
differences that lead to the production of
different proteins, which drive phenotypic
diversity. Whether a gene is expressed in a
speciﬁc cell at a given moment in time
depends on a multitude of regulatory
proteins and biochemical steps. Random-
ness and biological “noise” are present in
every biochemical process, especially in the
epigenetic modiﬁcation of DNA and the
transcription and translationof genes.Thus,
epigenetic and gene expression variability
are key contributors to phenotypic
differences.
Here, we distinguish between different
types of variability at different organiza-tional levels, speciﬁcally: 1) cell-to-cell variability in a population
of cells; 2) inter-individual variability of multi-cellular organ-
isms; and 3) variability across populations and species. Cell-to-
cell variability, for example, is important in shaping cell fate
determination and plays a key functional role in cellular
differentiation.[3,4] Also, it is thought to be required for
population robustness and higher-level function ofmulti-cellular
organisms.[5] For example, variability in a population of cells
allows essentially binary decisions, such as undergoing cell
death, to turn into more ﬂexible and ﬁne-tuned responses at the
level of the cell population as a whole. This creates an adaptive
advantage and provides beneﬁts in survival.[6,7] These effects
have mainly been investigated in unicellular organisms, but are
known to also be relevant for human adaptation.[8] Presumably,
they are a unifying feature of biological systems at all levels, with
variability forming the basis for positive natural selection,
thereby enabling evolution.[9] In fact, the above-described
mechanisms may be comparable to how evolution makes
ecosystems robust through the generation of biodiversity.[10]
The different levels of variability are related to each
other.[11–13] There also exists a direct correspondence between
the measurement of variability at one time point in a population
of, for example, 1000 cells and the measurement of variability of
one cell at 1000 time points[14]—a concept known as ergodic
hypothesis. It has further been shown that cell-to-cell gene
expression variability in yeast populations correlates with
variability across populations, and—to a lesser extent—across
species.[12,13,15] For example, Dong et al.[15] showed that
ﬂuctuations in gene expression between isogenic yeast cells
correlate well with expression variation within individual cells,
and this variability also correlated with variability betweenAuthors. BioEssays Published by WILEY Periodicals, Inc
www.advancedsciencenews.com www.bioessays-journal.comdifferent yeast strains or species. The positive correlation
between different levels of variability was maintained under
varying environmental conditions. Similar results were obtained
by a study investigating the relationship between transcriptional
variation across mammalian individuals and species in limb
development,[9] showing that variability in gene expression levels
across four different species of mammals was correlated with
intra-species expression variability among individual animals.
Recently, large collections of human epigenomic and tran-
scriptomic data have become available, facilitated by consortia
such as the NIH Roadmap Epigenomics project,[16] the
International Human Epigenome Consortium (IHEC, http://
ihec-epigenomes.org) and the associated BLUEPRINTproject[17]
(http://www.blueprint-epigenome.eu). In the context of BLUE-
PRINT, we analyzed differential variability across primary
immune cells derived from healthy individuals and aimed to
characterize the extent and functional implication of epigenetic
and transcriptional variability in different immune cell types.[18]
In a previous study, we had investigated gene expression
differences between the two main subtypes of chronic
lymphocytic leukemia, known to show only minimal differential
expression,[19,20] and observed strongly increased gene expres-
sion variability in the more aggressive subtype of the disease.[21]
While epigenetic analyses of monozygotic twins discordant for
type 1 diabetes revealed no differences in mean DNA
methylation, we found substantial enrichment of hypervariable
loci among the siblings with the disease.[22] Together, these
studies were among the ﬁrst to classify disease status or
aggressiveness based on variability, where the classical compar-
ison ofmeanDNAmethylation or gene expression levels was not
informative. The data highlight the importance of inter-
individual epigenetic and transcriptional variability and its
application to uncovering disease biology.
In this review, we focus on epigenetic variability (i.e., DNA
methylation and chromatin structure) and transcriptional
variability (i.e., gene-level expression variability). We do not
discuss allele-speciﬁc expression or transcript and isoform
variability. We distinguish between two main types of biological
variability: 1) inter-individual variability, that is the differences
between individuals; and 2) intra-individual variability or cell-to-
cell variability, that is, differences across single cells of a
population. We deﬁne sources and determinants of epigenetic
and transcriptional variability and provide examples of their
functions and implications in health and disease. Last, we
discuss questions and challenges in the analysis of variability,
and consider how these concepts and approaches could be
applied to the development of new therapeutic approaches and
personalized medicine.2. Biological Variability Derives From Distinct
Sources
There are many possible sources of epigenetic and transcrip-
tional variability, which can be divided into three main
categories: 1) individual-intrinsic factors; 2) environmental
factors; and 3) random ﬂuctuations, also referred to as
stochasticity. These different sources of variability are further
described below and summarized in Figure 1.BioEssays 2017, 1700148 1700148 (2 of 11)2.1. Individual-Intrinsic Factors
The expression variability of a gene is, in part, encoded by its
genomic context (e.g., promoter DNA sequence)[23] and further
controlled by the epigenome[11] (see Section 3). Additional, non-
genetic, individual-intrinsic factors such as sex, age, and
environmental factors, further inﬂuence both epigenetic and
gene expression variability.2.1.1. Genetic Variation
Most studies on gene expression variability thus far have focused
on the mapping of genetic variants associated with gene
expression changes across individuals,[13] so-called expression
quantitative trait loci (eQTL). These studies quantify the effect
that single-nucleotide polymorphisms (SNPs) and copy number
variations (CNVs) have on gene expression. Atlases of cis- and
trans-eQTLs across a vast number of cell types, tissues, and
environmental conditions have been generated. Remarkably, up
to 90% of expressed protein-coding genes have an eQTL in at
least one tissue.[24] The amount of gene expression variation
explained by genetic variability is typically small (<5% for the
majority of genes[4,25,26]). Thus, common genetic variants only
explain a small proportion of total expression variation.
However, their effects are still stronger than those of major
demographic factors such as age and sex.[25] Genetic variation
also has an impact on the epigenome, and there is a high level of
interaction between genetic, epigenetic, and transcriptional
variability.[26–28] Of note, genetic variants can affect both the
mean and variance of a quantitative phenotype.[6,29,30]2.1.2. Sex
DNA methylation and gene expression differences between
males and females have been reported for both autosomal genes
and genes expressed on sex chromosomes.[31,32] These differ-
ences are particularly important in the context of the immune
system, as women exhibit generally stronger immune responses
than men, and many auto-immune diseases such as rheumatoid
arthritis and multiple sclerosis have a higher incidence in
females.[31,33]2.1.3. Age
Besides sex, age is the most important non-genetic source of
inter-individual variability (recently reviewed by Tejedor and
Fraga[34]). It has been shown that epigenetic marks change over
life to such an extent that an individual’s age can be predicted
from its DNA methylation proﬁle.[35,36] Further, the methylome
and transcriptome become more and more diverse with
increasing age. This phenomenon of increased variability with
age occurs both in genetically identical twins[37,38] and unrelated
individuals[8,35,39] and is also referred to as “epigenetic drift.”
A recent study by Jenkinson et al.[40] showed that DNA
methylation entropy (a measure of disorder or randomness)
increased in older individuals, with these changes being more© 2017 The Authors. BioEssays Published by WILEY Periodicals, Inc
Figure 1. Overview of the different types and sources of epigenetic and transcriptional variability. Epigenetic and transcriptional variability exist between
different individuals (i.e., inter-individual variability) and between different cells (i.e., cell-to-cell variability). The bar plot illustrates the levels of an
epigenetic mark (e.g., DNA methylation) or gene expression measured in a specific cell type or individual. Sources of such variability, including
individual-intrinsic and environmental factors, are also shown. Credits: The immune response, BigPicture (http://bigpictureeducation.com).
www.advancedsciencenews.com www.bioessays-journal.compronounced than age-associated differences in mean DNA
methylation. An extraordinarily long-lived human population
was shown to exhibit less pronounced epigenetic drift,[41]
pointing to an important implication of biological variability in
aging and its association with life- and healthspan.[42] The
epigenetic component of accumulating environmental exposure,
and its interplay with genetic and stochastic factors, provides an
explanation for the frequently observed discordance of disease
between monozygotic twins and the increase of common
diseases with age.[43]2.1.4. Other Non-Genetic Individual-Intrinsic Factors
Related to aging, variability also occurs over an individual’s
lifetime due to development, growth, pregnancy, and meno-
pause. At the cellular level, the distinct stage of the cell cycle is
another important source of variability.[44,45,46]BioEssays 2017, 1700148 1700148 (3 of 11)2.2. Environmental Factors
The epigenome forms the intersection between the genome and
the environment. Many lifestyle and behavioral factors have been
shown to inﬂuence the epigenome—and as a consequence—the
transcriptome and the resulting phenotype. Such alterations can
have a long-lasting impact, and may potentially even be passed
on to subsequent generations.[47,48] Environmental factors
impacting the epigenome and transcriptome include prenatal
exposures, childhood adversities, nutrition, physical activity,
exercise, stress, exposure to pollutants and toxins, smoking,
climate, season, daylight, culture, education, socio-economic
factors, and many others.[31,39,49–52]
At the cellular level, the micro-environment plays an
important role; for example, hematopoietic stem cells from
different micro-environments (i.e., the bonemarrow, cord blood,
and fetal liver), exhibit different DNA methylation proﬁles.[53]
The location of a cell within a population and its local© 2017 The Authors. BioEssays Published by WILEY Periodicals, Inc
www.advancedsciencenews.com www.bioessays-journal.comcrowdedness are also a source of variability, as well as cellular
volume and mitochondrial content.[44,54]
2.3. Stochasticity
Stochasticity is particularly important at the level of cell-to-cell
variability in biochemical processes. This stochasticity is thought
to contribute to cell differentiation, adaptation to changing
environmental conditions (e.g., rapid response to external
stimuli), and population robustness.[3,7,12]
At the level of individual cells and the level of multi-cellular
organisms, each of these sources of variability also leads to
temporal variation. The accumulation of environmental expo-
sures contributes to the strong epigenetic changes observed with
increasing age.[44] Most of the variability is determined by a
complex combination and interaction of different sources of
variation. The relative contributions of different sources of
variability can be different in distinct cell types, and are only
starting to be revealed. For example, DNAmethylation variability
of Tcells was found to be associated with donor age at many loci,
while in monocytes, DNA methylation variability associated
more often with season.[18] Interestingly, we found more than a
thousand genes with small but signiﬁcant sex-speciﬁc differen-
tial expression in neutrophils, while monocytes and T cells
showed less sex-speciﬁc gene expression.[18] Thus, variability can
be different for the same gene across cell types and distinct
tissues, and can be inﬂuenced by distinct factors.3. Chromatin Properties and Gene Regulatory
Networks Control Gene Expression Variability
Expression variability for a single gene can be controlled by
different mechanisms, including: 1) local genome properties
such as the DNA sequence and epigenetic landscape; 2) 3D
chromatin structure; and 3) the gene’s position in regulatory
networks (see Figure 2).3.1. Epigenetic Mechanisms
Chromatin properties at gene promoters and bodies can impact
transcriptional variation.[11,46,56] TATA boxes are sequence
motifs that can be found at the promoters of genes displaying
variability and plasticity in changing environments. The
mechanism through which the presence of TATA boxes affects
expression is partly dependent on the different nucleosome
architecture favored by this motif.[57] A recent single-cell RNA
sequencing study of mouse embryonic stem cells reported that
active chromatin states in gene bodies led to reduced gene
expression variability and that gene body chromatin marks are
more important determinants of gene expression variability than
promoter sequence features.[46] Alemu et al.[11] showed that
reduced variability associated with active chromatin marks (such
as H3K4me3 and H3K36me3, and DNaseI hypersensitivity) and
increased variability associated with repressive marks such as
H3K27me3 (a mark that is catalyzed by the Polycomb complex
often found to mediate the silencing of developmentally
important genes). Using single-cell transcriptomics, it was
shown that a subset of genes that are active despite beingmarkedBioEssays 2017, 1700148 1700148 (4 of 11)by H3K27me3 and bound by Polycomb displayed higher
variability in mouse embryonic stems cells.[58] This is thought
to be due to different bursting dynamics characterizing
transcription at these genes, which show high expression levels
despite carrying repressive chromatin marks. Polycomb could
modulate the frequency of transcriptional bursting, affecting
expression variability independently of its mean levels.[58] This
enhanced switching of the transcriptional state from “OFF” to
“ON” in a subset of Polycomb targets could produce expression
ﬂuctuations in single cells, which have been observed in
embryonic stem cells.[59] Polycomb was also shown to modulate
methylation variability,[40] which, in turn, can lead to gene
expression variability.[18,26,60]
Indeed, whenwe correlated the DNAmethylation values of loci
exhibiting high variability in DNA methylation with the
corresponding gene expression values derived from the same
samples, we observed a signiﬁcant correlation between DNA
methylation and gene expression levels in up to 33% of the
hypervariable loci.[18] Interestingly, we also observed high gene
expressionvariability forgeneswithvery consistent (i.e., stable,not
variable)DNAmethylationat theirpromoters.Thepromoterswith
either highly variable or very consistent DNA methylation levels
werealso found toexhibitmore transcription factor bindingmotifs
than other promoters.[18] These ﬁndings indicate a complex
regulatory control exerted on the genes found to be at the extreme
ends of promoter DNAmethylation variability (either very low or
very high). RegardingDNAmethylation variability at gene bodies,
our data suggested that gene expression variability increases with
DNA methylation variability.[18]
High mean methylation levels of gene bodies have been
associated with reduced transcriptional noise,[61] possibly
because methylation excludes the deposition of the H2A.Z
histone variant, which was found to reduce expression and
increase the variability and plasticity of expression regulation in
Arabidopsis.[62] Deposition of H2A.Z in promoters has an impact
on the nucleosome conﬁguration[63] and DNA methylation
control of H2A.Z deposition might further affect transcriptional
variability through promoter architecture.3.2. 3D Chromatin Structure
Recent technological advances have allowed us to map the 3D
conformation of chromatin and to uncover the spatial
organization of the genome inside the nucleus. These experi-
ments have revealed the complexities of genome folding at
different scales and levels. Chromatin loops pervade the genome
connecting genomic regions at various linear distance ranges.
Loops are thought to be organized in regions of dense chromatin
interactions insulated by speciﬁc proteins from other similar
regions, so-called topologically associated domains (TADs).[64]
Chromatin loops are assembled into separate compartments
characterized by distinct levels of activity and transcriptional
output.[65] Although similar TADs were found across develop-
mental stages, single cells, individuals, and even species, their
assignment to different compartments is much more vari-
able[66,67] and the compartments themselves are probably more
related to transcriptional programs and phenotypes. Therefore, it
is conceivable that variability in expression across single cells© 2017 The Authors. BioEssays Published by WILEY Periodicals, Inc
Figure 2. Epigenetic patterns, chromatin structure, and gene regulatory networks control gene expression variability. A) While active chromatin marks
such as H3K4me3 and H3K36me3 and DNaseI hypersensitivity have been shown to associate with reduced gene expression variability, repressive marks
such as H3K27me3, deposited by members of Polycomb, are associated with increased gene expression variability, possibly through an effect on
transcriptional bursting. B) 3D chromatin contacts can be mapped using chromosome capture methods. These contacts form a network where nodes
are chromatin fragments and edges are drawn when the fragments interact in 3D. Nodes that are colored have high gene expression variability. Using
Chromatin Assortativity (ChAs),[55] we detected a tendency for highly variable genes to preferentially connect in 3D. C) In regulatory networks, central and
highly connected genes have been found to show low gene expression variability.
www.advancedsciencenews.com www.bioessays-journal.comarises as a consequence of the speciﬁc assignment of genomic
regions to compartments with different levels of activity in
different cells.
Motivated by these ﬁndings, we investigated gene expression
variability of monocytes, neutrophils and Tcells in the context of
3D chromatin interactions. To this aim, we leveraged promoter-
centered chromatin contact maps generated using the Promoter-
Capture HiC protocol.[68] These data provide information on 3D
interactions between distant genomic regions. We used a novel
statistical method (ChAs) that assesses the relationship between
chromatin properties and 3D chromatin interaction networks
through a measure called assortativity,[55] which we applied to
expression variability. We found that chromatin fragments that
overlap genes with high expression variability are preferentially
connected with each other in the 3D contact map of the
corresponding cell type (manuscript in preparation).
Our results support the hypothesis that chromatin structure
can be related to transcriptional variability. Indeed, Kar et al.[58]
reported that gene expression variability could be associated with
speciﬁc regions along chromosomes. The availability of more
detailed maps of 3D chromatin structure, combined with single
cell transcriptomics, will allow us to further characterize the
relationships between nuclear organization and variability at
different levels.BioEssays 2017, 1700148 1700148 (5 of 11)3.3. Gene Regulatory Networks
An additional factor affecting expression variability is the gene’s
context within a regulatory network. For example, genes with
high expression variability were found to be less central in
signaling networks and less connected, especially in stem cells,
whereas the most connected genes were shown to be the stable
elements of pluripotent regulatory networks.[66,67] Speciﬁc
network motifs, such as feed-forward loops, also affect variability
of the regulated genes.[66] Moreover, the variability of genes could
be directly affected by variability in their regulators. In fact, a
recent model for the evolution of gene regulation in bacteria
suggests that the propagation of variability of expression from a
transcription factor to its target could be the most primordial
type of gene regulation.[69]
On a more global level, integrating gene expression datasets
with protein-protein interaction networks has made it possible to
identify characteristic expression conﬁgurations related to
disease, cancer stemness and intra-tumor heterogeneity.[70,71]
Deﬁning new concepts of network entropy or energy[40] allows
the characterization of the association between the expression
levels of single genes and the position of these genes in the
interaction network. These analyses provide a connection
between molecular data and phenotypes such as transcriptome© 2017 The Authors. BioEssays Published by WILEY Periodicals, Inc
www.advancedsciencenews.com www.bioessays-journal.comvariability and plasticity, which are seen as global emergent
properties of the gene network.
Taken together, the genomic and epigenetic context of a gene, as
well as its position in interaction and regulatory networks, are
important mechanisms impacting expression variability. Under-
standing how these mechanisms interact will shed light on how
this biological variability is regulated andharnessed in evolution to
ensure cell survival and adaptability in changing environments.4. Variability Plays a Key Role in Human
Health and Disease
Epigenetic and transcriptional variability play key roles in
human physiology, particularly in the functioning of the human
immune system.[31,33,72,73] Conversely, increased variability is
also associated with pathogenesis, disease progression, and
aggressiveness, and resistance to therapy.[21,22,74–77] Both aspects
can be linked back to the same underlying biological principle of
variability, providing an evolutionary advantage and thus leading
to enhanced survival: cancer cell populations, for example, are
known to be highly heterogeneous, and this heterogeneity is
strongly associated with disease progression and severity, and
therapeutic resistance of the cancer.[74,78] Thus, in this context,
variability is detrimental to the host organism but beneﬁcial to
the population of malignant cells.4.1. Variability in the Immune System
Variability is a crucial aspect of the human immune system,[33] at
both the inter- and intra-individual level. The human immune
system shows a high level of variability and constitutes an
incredibly adaptive defense mechanism. This variability is
particularly important for migratory cells of the immune system
facing highly changeable environments such as infections and
invasion of pathogens. Indeed, migratory immune cells, such as
monocytes, neutrophils, and lymphocytes, exhibit strong
phenotypic plasticity and adaptability.[72]
We found particularly high DNA methylation and gene
expression variability in neutrophils compared tomonocytes and
T cells.[18] This inter-individual variability could possibly be
related to intra-individual variability. The corresponding plastic-
ity of these immune cells would enable rapid adaptation to
changing external conditions and, importantly, an effective
defense against invading pathogens. In our study, neutrophil-
speciﬁc hyper-variable genes were enriched for functions critical
to adaptability and rapid reactions to external stimuli, such as
signaling and motility, supporting this hypothesis.
In summary, a high level of immune cell adaptability to
environmental changes and functional diversity of immune cells
are important for a healthy immune system.[72,73]4.2. Variability in Cancer
Alongside variability at the genetic level, there is a substantial
contribution of non-genetic variation to cancer development,
from precursor cells through all stages of tumor progression toBioEssays 2017, 1700148 1700148 (6 of 11)metastasis and disease relapse.[74,79,80] Increased DNA
methylation variability in normal tissue can be predictive of
neoplastic transformation years before the cancer develops.[75]
Furthermore, tissue DNA methylation has been shown to
explain 77% of the variance of the lifetime risk of cancer.[76]
A general loss of epigenetic stability leads to increased
epigenetic and transcriptional variability in cancer.[77] Epigenetic
alterations often target enhancer chromatin states that do not
only affect the mean level of transcription, but can also increase
its variability, possibly leading to intra-tumor heterogeneity.[80]
Neoplastic transformation is thought to revert the epigenetic
state to more closely resemble stem cells, with high self-renewal
potential and/or cells similar to unicellular organisms that
achieve adaptability through increased variability.[74,78] In
support of this hypothesis, it has been reported that loci that
are important in normal cellular differentiation show hyper-
variability in cancer.[3] Cancer cells adapt rapidly to changing
environments such as alterations in oxygen levels due to
neovascularization or necrosis, or metastasis to new micro-
environments.[77] Feinberg et al.[74,81] noted that the constitutive
activation of enhanced epigenetic plasticity in cancer leads to
classical cancer hallmarks such as inﬂammation, invasion, and
proliferation, and recent literature suggests that epigenetic
plasticity gives rise to all known hallmarks of cancer.[79]
Epigenetic alterations are important in tumor evolution.
There is a widespread interdependence of genetic and epigenetic
variation[82]; however, epigenetic alterations have been reported
to diversify at rates that are orders of magnitude higher than
those of somatic genetic alterations.[83] Considerable epigenetic
reprogramming has also been observed between primary
tumors and metastases with little genetic differences.[84]
Strikingly, all cancers that have been investigated thus far with
respect to epigenetic or transcriptional variability, showed a
strong increase of variability in tumor samples compared to
matched normal tissue.[3,74,77] In addition, the differences in
variability between cancer and normal samples are remarkably
higher than differences in mean levels.[3,43,75,77]4.3. Variability in the Emergence of Therapeutic Resistance
Heterogeneity indisease isalsokey in therapeutic resistance.Cancer
relapse has traditionally been associated with genetic differences of
cellular subclones, proliferative status, or the micro-environment
enabling some cells to survive treatment.[85] However, there is
accumulating evidence that the variability of cells in therapeutic
response is governed by non-genetic factors.[85,86] Even within a
subclone, cells display variability leading to differences in function
and unequal responsiveness to therapy, and therefore allowing a
subset of cells to escape treatment.[87]
Resistance arises through a combination of stochastic
ﬂuctuations, adaptation, and epigenetic inheritance.[88–90] For
example, variability in protein levels of receptor proteins
mediating cell death was linked to cells escaping tumor necrosis
factor related apoptosis-inducing ligand (TRAIL) exposure.[85]
Similarly, cell-to-cell variation in p53 expression was reported to
enable cells to survive in response to chemotherapy.[91] Escaping
cells are not only resistant to death but also protected against
future death stimuli.[90]© 2017 The Authors. BioEssays Published by WILEY Periodicals, Inc
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responses has typically been associated with intra-tumor
heterogeneity,[89,91] yet variability and its prognostic value is
not assessed in most clinical trials.[89] It has already been
demonstrated that intra-tumor epigenetic heterogeneity is a
valuable prognostic marker.[89,92] In chronic lymphocytic leuke-
mia, for example, DNA methylation signatures provide impor-
tant information about clinically relevant disease
subgroups,[93,94] and Shefﬁeld et al.[95] reported that DNA
methylation patterns of Ewing sarcoma tumors reﬂected a
continuous disease spectrum. Heterogeneity was not due to
genetic variation in these diseases, and it has been hypothesized
that differing DNA methylation proﬁles reﬂect the differentia-
tion stage of the cell from which the tumors originate.[93,95] For
many other cancer types, however, the picture is less clear.[89] In
solid tumors, additional variability can come from tumor-
adjacent stroma cells with different epigenetic and transcrip-
tional proﬁles. Therefore, it is important to characterize the
variability present in normal samples as well.[89] Taken together,
both epigenetic and transcriptional variability may serve as
effective biomarkers for personalized medicine.[75,80,89]
An improved understanding of both intra- and inter-
individual variability and disentangling the relationship between
different layers of variability and the underlying mechanisms
will be key to achieve better therapeutic outcomes.[31] In
particular, the integration of normal tissue epigenomics and
variability across individuals will be essential to promote the
understanding of onset and heterogeneity in disease.[80]5. Current Challenges and Outlook
Given the increasing attention of the biomedical community on
the topic of variability and the wealth of data being produced, we
argue that a number of challenges in the ﬁeld need to be
considered and overcome. Below, we distinguish and discuss
1) methodological and technical challenges; 2) challenges in
advancing fundamental biological understanding; and
3) challenges in translating this knowledge into the clinic and
health care management.5.1. Methodological and Technical Challenges
A critical methodological issue in the study of variability is
teasing apart technical variability from biological variability, or in
other words, improving ways to remove technical variability
without underestimating or compromising the ability to detect
biological variability. Even subtle differences in sample collec-
tion, handling, transport, storage, experimental procedures,
reagents, instruments, and other acts of measuring will lead to
technical variability. An intriguing example is described by
Lithgow et al.[96] in a comment about the “long journey to
reproducible results” across laboratories working on aging in
worms. All factors potentially contributing to variability should
be minimized as much as possible by applying a strict
standardization of every implicated procedure, and by collecting
a sufﬁcient number of measurements and replicates. However,
technical noise is also inherent to sample processing techniquesBioEssays 2017, 1700148 1700148 (7 of 11)such as microarray hybridization or sequencing. Thus, the
successful detection and removal of technical variability is
crucial for the subsequent computational data processing.
This is particularly relevant in the analysis of single cell data,
which is still facing limitations due to low signal resolution and
reduced signal-to-noise ratio compared to the analysis of data
derived from traditional bulk sample approaches.[89,97] Major
advanceshave alreadybeenachieved,[98,99] andas theﬁeld continues
to grow, we expect these hurdles to be overcome in the near future.
Methods integratingdifferent layersof regulation insinglecellshave
already been developed[100–102] and will provide unprecedented
insights into cell-to-cell variability inmolecular regulatory networks
and the interactions and relationships between different layers of
gene regulation and cellular phenotypes.
Another aspect often hindering the meaningful analysis of
biological variability is reduced statistical power, as the sample
size for variability analyses needs to be considerably increased
compared to traditional studies of mean differences between
disease and control groups, for example.[103] Furthermore, the
correlation structure between variability and other features must
be taken into account. For example, increased gene expression
variability is associated with transcript length, while the number
of expressed transcripts shows a strong negative correlation with
gene expression variability.[46] Technical variability due to
intrinsic experimental noise is greater for lowly expressed genes
than for those expressed at high levels.[104,105] In the simplest
case, this can be due to the law of large numbers: a difference of
one or two reads has a bigger impact on a lowly expressed gene
with few reads than on a highly expressed gene with many reads.
For DNA methylation, there also exists a relationship between
mean DNA methylation levels and variability, with increased
variability generally observed for intermediate DNA methyla-
tion.[106] Thus, it is critical to obtain a measurement of variability
that is independent of the mean to ensure to not confound
changes in variability with shifts in mean.5.2. Challenges in Advancing Fundamental Biological
Understanding
Beyond the technical and methodological challenges described
above, the analysis of variability also opens new questions related
to the interpretation of the underlying biological mechanisms.
For example, it remains difﬁcult to disentangle the interdepen-
dencies and relationships between different layers of gene
regulation and how, in combination, they lead to variability and
plasticity in phenotypes.[31,107] How the organization of
the genome inside the nucleus could potentially modulate the
variability of methylation and expression in different parts of the
genome also remains unknown. Variability might be affected by
properties of the DNA at different levels, from the base-pair/
nucleosome scale all the way to the general 3D organization of
the DNApolymer inside the nucleus. Recent results in advanced
microscopy suggest a very ﬂexible and stochastic distribution of
nucleosomes on the DNA, disfavoring the commonly accepted
concept of a regular organization of DNA into a 30 nm-ﬁber
structure.[108,109] The characteristics of nucleosome organization
are likely to affect pluripotency and cell fate speciﬁcation, which© 2017 The Authors. BioEssays Published by WILEY Periodicals, Inc
www.advancedsciencenews.com www.bioessays-journal.comsuggests that the underlying biology that we are starting to
discover will shed further light on new determinants of gene
expression variability and phenotypic plasticity.
Another unresolved question is the relative contribution of
different sources of variability to the phenotype. The mapping of
environmental, genetic, and non-genetic factors has already
revealed important associations with inter-individual variability
of immune cell function.[18,26,110] As described above, variability
is also observed due to stochasticity, which is thought to form the
basis of adaptation and population robustness. However, a study
by Battich et al.[44] argues that the contribution of stochastic
events to variability might be smaller than previously thought.
The authors reported that variability between genetically
identical cells exposed to the same culture conditions is only
minimally stochastic and can be predicted with multivariate
models of the phenotypic state and population context of
single cells. High-content imaging-based transcriptomics in
single human cells showed that stochastic ﬂuctuations in gene
expression are buffered by nuclear retention, indicating that
cellular compartmentalization conﬁnes transcriptional noise to
the nucleus, where variability was shown to be higher than in the
cytoplasm. Therefore, cellular compartmentalization acting as a
passive noise-ﬁlter is an effective mechanism to buffer stochastic
ﬂuctuations arising from transcriptional bursts for most
genes.[44,111] On the other hand, altered chromatin mobility
between different sub-compartments of the nucleus has been
associated with increased stochastic variation, along with
dysregulated spatial separation between active and inactive
chromatin environments.[80] The extent of the contribution of
stochastic events to phenotypic variation of multi-cellular
organisms remains to be determined.
The observations on buffering ﬂuctuations through cellular
compartmentalization could partly explain why the correlation
between gene expression and protein levels is often weak.[8,112]
The translation of RNA expressed from the same gene in a single
cell has been shown to be very variable and to occur in bursts as
for gene expression.[112] The regulation of protein synthesis
could occur globally, or act on each RNA molecule individually
and be context dependent,[113] for example, in time (e.g., cell
cycle position) and space (e.g., subcellular location).[107,112] It has
also been shown that eQTLs tend to have reduced effect size on
protein levels, and protein QTLs often do not show effects on
RNA and are thus likely to arise from post-translational
regulation.[114]5.3. Challenges in the Translation to the Clinic and Health
Care Management
The ultimate challenge ahead is to translate these fundamental
biological insights into the clinic and health care management.
Gaining knowledge of the different layers of variability and their
relation to the phenotype, as well as how variability is generated,
controlled, and maintained mechanistically will be fundamental
to broaden our understanding of human health and disease. For
example, variability could be exploited to achieve a speciﬁc
immune response against a pathogen or disease.[31] Another
approach would be to reduce variability in diseases that thrive on
increased variability and dysregulation. There is great potentialBioEssays 2017, 1700148 1700148 (8 of 11)for drugs reducing epigenetic and transcriptional variability via
epigenetic modiﬁcations, as these are generally reversible.[89]
Furthermore, it is vital to take inter-individual variability into
account in clinical research to achieve better patient stratiﬁcation
and more tailored therapies. For example, individual epigenetic
and transcriptional proﬁles can be used to predict drug
response.[115,116] Host-intrinsic factors such as age, sex, or
genetic differences due to ethnicity can also cause very different
responses to treatments and should be taken into account. There
is a strong bias toward white Western participants in clinical
trials, and a number of drugs have been shown to be harmful to
other ethnic groups.[117,118] Thus, diversity of participants in
research studies and clinical trials is essential, and we need to
shift the focus onto the variability between individuals, instead of
average responses.
Taken together, an increased understanding of biological
variability and taking both inter- and intra-individual variability
into account in healthcare management and therapeutic
approaches will be fundamental to promote human health by
personalizing prevention, diagnosis, and treatments.6. Conclusion
The advancement of single-cell technology and the generation of
large-scale multi-omics data enable deeper investigations into
the essence of variability in biological systems at the intra- and
inter-individual levels. Several factors might underlie variability,
such as individual-intrinsic, environmental, and stochastic
effects. We have discussed how genetic and epigenetic factors
can affect variability in the expression of speciﬁc genes, and how
this might be inﬂuenced by chromatin organization in the
nucleus and the genes’ context in interaction networks. Together,
epigenetic and transcriptional variability ultimately affect
phenotypic heterogeneity and plasticity, an essential character-
istic in human health and disease.
A better understanding of variability in both health and
disease will pave the way for improving human health care.
Elucidating the interaction between genetic and non-genetic
individual-intrinsic factors and the environment, as well as how
they inﬂuence the phenotype through epigenetic and transcrip-
tional effects, will be crucial.[110,119] A precise understanding of
cell- and individual-intrinsic variability, the environmental
sources of variability, and how these effects are propagated
and accumulate throughout life will also allow to reveal to what
extent environmental or behavioral intervention could have an
impact on modulating disease risks.[33] This way, personalized
monitoring and adaptation of lifestyle factors such as diet or
physical activity[120,121] could enable the combination of
precision medicine with disease prevention, the ultimate goal
of successful health care management. That this is achievable
has been successfully exempliﬁed by the Pioneer 100 Wellness
Project (P100)[121] and the Blue Zones Vitality Project,[122] which
showed that modulating the environment and behavior of a
population can indeed lead to improved health and life-
expectancy.
Thus, by bringing variability into the focus, we hope to look
forward into a future of improved therapeutic approaches,
personalizedmedicine, and preventive health care management.© 2017 The Authors. BioEssays Published by WILEY Periodicals, Inc
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